EurekAlert!

Gliadel® Wafer demonstrates long-term survival benefit for patients with high-grade malignant glioma

MGI PHARMA, INC. (Nasdaq: MOGN) today announced the publication of long-term (56 month) follow-up data showing that Gliadel® Wafer provides a durable long-term survival benefit for patients with ...
The Baltimore Sun

FDA OKs wider use of Guilford’s Gliadel

Guilford Pharmaceuticals Inc. said yesterday that the Food and Drug Administration approved the use of its Gliadel wafer as a first-time treatment for malignant brain tumors, handing the Baltimore ...
California Healthline

Medicare To Begin To Cover Expensive Therapy for Patients With Brain Cancer

Medicare officials on Tuesday announced that the program will begin to cover Gliadel Wafer therapy, an "expensive" treatment manufactured by Guilford Pharmaceuticals that can improve survival rates ...
Pharmabiz

Eisai divests US rights for Gliadel Wafer to Arbor Pharmaceuticals

Eisai Co., Ltd., a US subsidiary of Eisai Inc. has entered into a definitive asset purchase agreement to divest US rights for its Gliadel Wafer (carmustine intracranial implant wafer), an ...
The Washington Post

FDA Approves Wider Use of Guilford's Brain-Cancer Wafer

correctionA headline in the Dec. 7 Business section incorrectly said the FDA approved a brain cancer treatment drug from Guilford Pharmaceuticals Inc. An FDA advisory panel endorsed wider use of the ...
ascopubs.org

Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma

A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth ...
BioWorld

FDA Approves Guilford's Gliadel As First-Line Therapy For Glioma

The FDA issued Guilford Pharmaceuticals Inc. approval to expand the use of the Gliadel Wafer as a first-line therapy for patients with high-grade malignant glioma. (BioWorld Today) ...
BioWorld

Guilford’s sNDA For Gliadel Wafer Turned Down By FDA

A difference in opinion apparently prompted the FDA to issue Guilford Pharmaceuticals Inc. a non-approvable letter rejecting a supplemental new drug application for use of the Gliadel Wafer in ...
The Baltimore Sun

Guilford gets OK to market cancer wafer FDA’s green light called a turning point for Baltimore firm; Brain tumor deterrent; Wall Street applauds ‘big achievement for a ...

Guilford Pharmaceuticals, the Baltimore based biotechnology company, won final Food and Drug Administration approval yesterday to market a biodegradable wafer shown to prevent the rapid recurrence of ...
The Washington Post

Guilford Shares Fall After FDA Rejects Bid on Wafer

Shares of Guilford Pharmaceuticals Inc. dropped 15 percent yesterday after the Baltimore company announced that the Food and Drug Administration rejected its bid for expanded use of its brain-cancer ...